Canopy Growth’s August Pivot: A Stock Between the Senate Floor and the Nasdaq Door

Canopy Growth shares slip to €0.7950, just above a 52-week low, as dual regulatory deadlines and a tax relief debate test the cannabis giant's financial runway.

The calendar is tightening for Canopy Growth. On Wednesday, shares slipped another 3.05 percent to €0.7950, leaving the stock just 6 percent above its 52-week low of €0.7500 — a level that puts the company back in familiar, uncomfortable territory. That floor is no accident: it’s the unofficial gateway to Nasdaq’s $1 minimum bid requirement, a threshold Canopy has danced with before.

A Double Deadline Takes Shape

Two events now bracket the company’s near-term outlook. On July 21, the DEA’s hearing on cannabis rescheduling concluded without a published outcome. The very next day, a group of 17 US senators — led by Cory Booker and Chuck Schumer — reintroduced the Cannabis Administration and Opportunity Act, a bill that would remove marijuana entirely from the Controlled Substances list. The timing was deliberate, but the legislative path is anything but clear: the CAOA has failed three times since 2021 to clear the Senate’s 60-vote threshold.

Then comes August 11. That’s when CEO Luc Mongeau takes the stage at the Canaccord Genuity Growth Conference in Boston to present what the company calls a “sharpened” cannabis strategy. Investors will be listening for something more concrete than policy hopes: how Canopy plans to turn the April 2026 Schedule III reclassification of FDA-approved and state-licensed medical cannabis into actual cash flow.

The Tax Trap That Won’t Go Away

The real prize is relief from Section 280E, the federal tax rule that prevents cannabis companies from deducting ordinary business expenses. The industry estimates the provision has cost it billions over the years. If Schedule III effectively kills 280E for medical cannabis, Canopy’s cash position changes overnight. If it doesn’t, the company remains stuck with an operating cash flow of negative $165.75 million from its last fiscal year — a burn rate that, against a market cap of €362.23 million, raises uncomfortable questions about financial runway.

But there’s a structural complication that tempers any optimism. Canopy’s US exposure runs through Canopy USA, a vehicle in which the parent holds only a non-controlling stake. That means Canopy cannot consolidate Canopy USA’s results into its own financial statements. Even if the DEA ruling or the CAOA opens the US medical market wider, the revenue benefit to Canopy’s own P&L remains opaque — a transparency gap that limits how much of a regulatory win actually shows up in the numbers.

A Familiar Nasdaq Shadow

The stock’s slide toward €0.7500 has revived talk of another reverse stock split. Canopy last resorted to that measure in December 2023 to maintain its Nasdaq listing. The board has not announced a new decision, but the math is becoming harder to ignore. A reverse split restores compliance on paper but does nothing for the company’s intrinsic value — and history suggests it can weigh on sentiment rather than lift it. The 50-day moving average at €0.8675 now serves as the first resistance level; a clean break below the March low of €0.7500 would almost certainly accelerate pressure for another capital restructuring.

The Bull Case: Cost Discipline Meets a Possible Floor

Optimists point to two levers that don’t depend on Washington. First, a cost-cutting program targeting annual savings of roughly $21 million is meant to carry Canopy through the current trough while keeping the option to scale quickly if the regulatory environment shifts. Second, the relative strength index sits at 38.8 — not yet oversold, but close enough that a single positive catalyst could trigger a short-term bounce. The stock’s annualized volatility of 36.44 percent amplifies that sensitivity: even a modest headline from the DEA or a credible EBITDA roadmap from Mongeau on August 11 could reverse the slide.

The stock currently trades 10.13 percent above its 52-week low, which some read as evidence of a floor forming. If Mongeau can outline a credible path to positive EBITDA by 2027, the narrative could shift from “policy hope” to “operational reality” — a transition that would mark a genuine buying signal for many investors.

The Bear Case: Structural Headwinds and a Distant High

The skeptics have numbers on their side too. The stock sits 15.59 percent below its 200-day moving average of €0.9786, a textbook sign of a sustained downtrend. The 52-week high of €2.00 is a reminder of how far sentiment has fallen. And while analysts expect a 71.4 percent improvement in earnings per share next quarter, it remains unclear whether that will come from operational savings alone or requires the immediate cash-flow benefit of 280E repeal.

Then there’s the legislative reality. Even if the CAOA gains momentum, the Senate process is measured in months, not weeks. The DEA’s rescheduling decision, by contrast, could land at any time — and would likely move the sector more immediately than a bill still searching for 60 votes. But for Canopy specifically, the non-consolidated structure of Canopy USA means any regulatory win will hit the income statement with a muffled impact.

What to Watch Between Now and Autumn

The stock’s immediate fate hinges on two unknowns without clear resolution dates: the DEA’s formal ruling on rescheduling and the board’s decision on whether to pursue another reverse split. As long as the €0.7500 support holds, the decline looks more like slow erosion than a collapse. A concrete signal from the DEA could shift sentiment across the entire cannabis sector, even if the direct financial benefit to Canopy remains muted by its corporate structure.

Mongeau’s August 11 presentation in Boston is the next hard date on the calendar. If he delivers a credible EBITDA target for 2027 and a clear plan for monetizing Schedule III, the stock may find its footing. If the presentation is vague or the cost savings fail to materialize, the 52-week low will become a test — and the Nasdaq compliance question will move from background noise to front-page urgency.